• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

    10/25/24 6:16:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MAIA alert in real time by email
    SC 13D/A 1 d902674dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    MAIA BIOTECHNOLOGY, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    552641 102

    (CUSIP Number)

    STAN V. SMITH

    1165 North Clark Street, Suite 600

    Chicago, IL 60610

    Telephone: (312) 943-1551

    With a copy to:

    Richard A. Friedman, Esq.

    Greg Carney, Esq.

    Sheppard Mullin Richter & Hampton LLP

    30 Rockefeller Plaza

    New York, New York 10112

    (212) 653-8700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 28, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     1   

     NAME OF REPORTING PERSONS

     

     The Stan V. Smith Trust Dated 1993

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     PF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     IL

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     1,547,933 (1)

        8  

     SHARED VOTING POWER

     

     0

        9  

     SOLE DISPOSITIVE POWER

     

     1,547,933 (1)

       10  

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,547,933 (1)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     6.32%(2)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (1)

    Represents 1,005,060 shares of common stock, $0.0001 par value per share (the “Common Stock”), of MAIA Biotechnology, Inc., a Delaware corporation (the “Company”) and 542,873 shares of Common Stock issuable upon the conversion of options and warrants exercisable within 60 days of the date hereof, for an aggregate beneficial ownership total of 1,547,933 shares of Common Stock.

    (2)

    Based on 24,509,687 shares of Common Stock outstanding as of September 30, 2024, calculated by adding (i) the 23,966,814 shares of Common Stock outstanding as of September 30, 2024 according to the Company’s records and (ii) the 542,873 shares of Common Stock beneficially owned by The Stan V. Smith Trust Dated 1993, which are issuable upon the conversion of options and warrants exercisable within 60 days of the date hereof.


     1   

     NAME OF REPORTING PERSON

     

     Stan V. Smith

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     Not applicable

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     US

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     1,547,933 (1)(2)

        8  

     SHARED VOTING POWER

     

     0

        9  

     SOLE DISPOSITIVE POWER

     

     1,547,933 (1)(2)

       10  

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,547,933 (1)(2)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     6.32%(3)

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    Stan V. Smith, as trustee of The Stan V. Smith Trust Dated 1993, may be deemed to be the beneficial owner of securities held by The Stan V. Smith Trust Dated 1993.

    (2)

    Represents 1,005,060 shares of Common Stock of the Company and 542,873 shares of Common Stock issuable upon the conversion of options and warrants exercisable within 60 days of the date hereof, for an aggregate beneficial ownership total of 1,547,933 shares of Common Stock.

    (3)

    Based on 24,509,687 shares of Common Stock outstanding as of September 30, 2024, calculated by adding (i) the 23,966,814 shares of Common Stock outstanding as of September 30, 2024 according to the Company’s records and (ii) the 542,873 shares of Common Stock beneficially owned by The Stan V. Smith Trust Dated 1993, which are issuable upon the conversion of options and warrants exercisable within 60 days of the date hereof.


    This Amendment No. 1 on Schedule 13D (this “Schedule 13D”) relates to the Issuer’s Common Stock and amends and further supplements the Schedule 13D originally filed on August 10, 2022 (as amended from time to time, the “Statement”) by Stan V. Smith and The Stan V. Smith Trust Dated 1993 (collectively, the “Reporting Persons”). The Reporting Persons are filing this Schedule 13D to report the purchase by the Reporting Persons of additional shares of Common Stock as disclosed in Items 3 and 5 below. Except as expressly set forth herein, there have been no changes to the Statement. Except as otherwise indicated, capitalized terms used and not defined in this Amendment No. 1 shall have the meaning assigned to such term in the Schedule 13D.

    Item 2. Identity and Background.

    This Statement is filed by (i) The Stan V. Smith Trust Dated 1993, and (ii) Stan V. Smith as Trustee of The Stan V. Smith Trust Dated 1993.

    Stan V. Smith is an independent director of the Company. The principal business address of Stan V. Smith is 1165 North Clark Street, Suite 600, Chicago, IL 60610. Stan V. Smith’s principal business is serving as the President of Smith Economics Group, Ltd. Stan V. Smith is a citizen of the United States of America.

    The principal business address of The Stan V. Smith Trust Dated 1993 is c/o Stan V. Smith, as Trustee, at 1165 North Clark Street, Suite 600, Chicago, IL 60610. The Stan V. Smith Trust Dated 1993 does not conduct any business. The Stan V. Smith Trust Dated 1993 was formed in the State of Illinois.

    The foregoing persons are sometimes referred to herein as a “Reporting Person” and collectively as the “Reporting Persons.” The Reporting Persons are filing this Statement jointly. Neither the fact of this filing nor anything contained herein shall be deemed to be an admission by any of the Reporting Persons that they constitute a “group.”

    None of the Reporting Persons or any of their partners, managers, officers or other controlling persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    None of the Reporting Persons or any of their partners, managers, officers or other controlling persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 3. Source and Amount of Funds or Other Consideration.

    On April 27, 2023, The Stan V. Smith Trust Dated 1993 purchased 133,300 shares of Common Stock in the Company’s follow-on offering for a total cost of approximately $299,925. On March 14, 2024, The Stan V. Smith Trust Dated 1993 purchased 170,940 shares of Common Stock and 170,940 warrants to purchase Common Stock for a total cost of approximately $200,000. On April 25, 2024, The Stan V. Smith Trust Dated 1993 purchased 147,492 shares of Common Stock and 147,492 warrants to purchase Common Stock for a total cost of approximately $300,000. The source of the funds was the personal funds of Stan V. Smith which were gifted to The Stan V. Smith Trust Dated 1993. Stan V. Smith, as trustee of The Stan V. Smith Trust Dated 1993, may be deemed to be the beneficial owner of securities held by The Stan V. Smith Trust Dated 1993.

    Item 4. Purpose of Transaction.

    The Reporting Persons acquired the Common Stock reported in this Statement for investment purposes. The Reporting Persons may in the future acquire additional Common Stock or dispose of some or all of the Common Stock held by the Reporting Persons in open-market transactions or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons may engage in short selling or hedging or similar transactions with respect to the Common Stock, on such terms and at such times as the Reporting Persons may deem advisable, subject to applicable law.

    None of the Reporting Persons has any present plan or proposal that would result in any of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right in the future to formulate any such plans or proposals, and to take any actions with respect to their investments in the Company, including any or all of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D.


    Item 5. Interest in Securities of the Issuer.

     

      (a)

    See responses to Items 11 and 13 on the cover page.

     

      (b)

    See responses to Items 7, 8, 9 and 10 on the cover page.

     

      (c)

    On September 30, 2024, The Stan V. Smith Trust Dated 1993 was granted 9,040 fully vested stock options pursuant to the Company’s 2021 Equity Incentive Plan. The options expire on September 30, 2034 and have an exercise price of $2.81. Stan V. Smith, as trustee of The Stan V. Smith Trust Dated 1993, may be deemed to be the beneficial owner of securities held by The Stan V. Smith Trust Dated 1993.

     

      (d)

    Not applicable.

     

      (e)

    Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Except as described under Items 3, 4 and 5 and as set out in Item 6, to the best knowledge of the Reporting Persons’, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between these shareholders and any other person with respect to any securities of the Company, including but not limited to transfer or voting of any securities of the Company, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, or a pledge or contingency the occurrence of which would give another person voting power over the securities of the Company.


    SIGNATURE

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct.

    In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Statement on Schedule 13D with respect to the Common Stock of the Company.

    Dated: October 25, 2024

     

    The Stan V. Smith Trust Dated 1993

    /s/ Stan V. Smith, as Trustee

    Stan V. Smith, as Trustee
    Stan V. Smith

    /s/ Stan V. Smith

    Stan V. Smith
    Get the next $MAIA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MAIA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MAIA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Stan bought $50,000 worth of shares (33,333 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      6/5/25 4:42:27 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Guerrero Ramiro bought $30,000 worth of shares (20,000 units at $1.50), increasing direct ownership by 4% to 588,218 units (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/12/25 4:14:02 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smith Stan bought $99,999 worth of shares (66,666 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/12/25 4:12:43 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MAIA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

      MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress, hosted by the Turkish Biochemical Society, to be held July 5-9, 2025, in Istanbul, Turkey. The poster presentations highlight MAIA's lead telomere-targeting agent and next-generation treatments. The first presentation will be delivered by MAIA Scientific Advisory Board member, Z. Gunnur Dikmen, M.D., Ph.D., Hacettepe University, Faculty of Medicine, Department of Biochemistry in Ankara, Turkey. Poster

      7/1/25 9:00:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

      Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

      6/24/25 8:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

      Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA's telomere-targeting agent ateganosine (THIO), sequenced with Roche's checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers. "In preclinical studies, ateganosine was found to be highly synergistic and effective in combination w

      6/18/25 9:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MAIA
    SEC Filings

    See more
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/25/25 9:55:20 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/24/25 9:15:10 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/18/25 9:25:54 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MAIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Guerrero Ramiro

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:17:45 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chaouki Steven M

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:16:50 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Louie Ngar Yee

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:16:10 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MAIA
    Leadership Updates

    Live Leadership Updates

    See more
    • MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

      Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

      6/24/25 8:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

      Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

      3/25/25 8:46:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

      Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos

      3/21/24 3:00:00 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MAIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

      SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 6:16:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MAIA Biotechnology Inc.

      SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 5:12:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MAIA Biotechnology Inc.

      SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 5:10:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care